{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:39:56Z","timestamp":1793425196330,"version":"4.5.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","funder":[{"name":"Clinical and Translational Science Center, Weill Cornell Medical College"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To compare the efficacy of 162 mg vs 81 mg aspirin daily for the prevention of preterm preeclampsia (less than 37 weeks of gestation) or preeclampsia with severe features among pregnant people at high risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>We conducted a pragmatic, randomized, open-label, blinded endpoint clinical trial. Pregnant people at high risk for preeclampsia were randomized to treatment with either 162 mg or 81 mg aspirin daily beginning before 16 weeks of gestation until term and followed up until 6 weeks postpartum. The primary composite outcome of either preterm preeclampsia or preeclampsia with severe features was adjudicated by independent researchers blinded to treatment group. Secondary outcomes were the components of the composite, adherence to therapy, and maternal and neonatal complications. The anticipated incidence of the primary composite outcome in the 81-mg group was 8.6%. We calculated that enrollment of 394 participants (197 for each group) would have 80% power to detect a 7.1% reduction in the primary outcome with 162 mg aspirin compared with 81 mg, assuming a two-sided \u03b1 of 0.05.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      Of 400 participants randomized, 365 had delivery data available and were included in the intention-to-treat analysis, with 184 participants in the 162-mg group and 181 in the 81-mg group. The incidence of preterm preeclampsia or preeclampsia with severe features was 26 of 184 (14.1%) in the 162-mg group compared with 31 of 181 (17.1%) in the 81-mg group (relative risk 0.83, 95% CI, 0.51\u20131.33,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =.4). Individual outcomes of preterm preeclampsia and term preeclampsia with severe features were similar between aspirin groups. Adherence rates ranged from 88% to 91% and 89% to 92% for the 162-mg group compared with the 81-mg group, respectively, across study visits. Singleton birth weight was slightly lower in the 162-mg group (2.9 kg vs 3.2 kg,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =.005). There were eight cases of placental abruption in participants randomized to 162 mg compared with 0 in those randomized to 81 mg (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =.013).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Among people at increased risk for preeclampsia, the rates of preterm preeclampsia or preeclampsia with severe features were similar to rates in those randomized to treatment with either 81 mg or 162 mg aspirin at less than 16 weeks of gestation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CLINICAL TRIAL REGISTRATION:<\/jats:title>\n                    <jats:p>ClinicalTrials.gov, NCT04070573.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000006100","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T17:00:11Z","timestamp":1764176411000},"page":"87-96","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Comparison of 162 mg and 81 mg Aspirin for Prevention of Preeclampsia"],"prefix":"10.1097","volume":"147","author":[{"given":"Amrin","family":"Khander","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlene","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Christos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Alcus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanvir","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Bush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diksha","family":"Deshmukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen T.","family":"Chasen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E.","family":"Riley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W.","family":"Skupski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phyllis","family":"August","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Line","family":"Malha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"R1-20260930","doi-asserted-by":"crossref","first-page":"544.e1","DOI":"10.1016\/j.ajog.2013.08.019","article-title":"Incidence of preeclampsia: risk factors and outcomes associated with early-versus late-onset disease","volume":"209","author":"Lisonkova","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"R2-20260930","first-page":"CD013632","article-title":"Antiplatelet agents for preventing pre-eclampsia and its complications","volume":"10","author":"Duley","year":"2019","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"R4-20260930","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ajog.2023.04.031","article-title":"Low-dose aspirin therapy for the prevention of preeclampsia: time to reconsider our recommendations?","volume":"229","author":"Horgan","year":"2023","journal-title":"Am J Obstet Gynecol"},{"key":"R5-20260930","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1001\/jama.2021.8551","article-title":"Aspirin use to prevent preeclampsia and related morbidity and mortality: updated evidence report and systematic review for the US Preventive Services Task Force","volume":"326","author":"Henderson","year":"2021","journal-title":"JAMA"},{"key":"R6-20260930","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ajog.2017.12.238","article-title":"Meta-analysis on the effect of aspirin use for prevention of preeclampsia on placental abruption and antepartum hemorrhage","volume":"218","author":"Roberge","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"R7-20260930","first-page":"CD004659","article-title":"Antiplatelet agents for preventing pre-eclampsia and its complications","volume":"18","author":"Duley","year":"2007","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"R8-20260930","doi-asserted-by":"crossref","first-page":"101000","DOI":"10.1016\/j.ajogmf.2023.101000","article-title":"Comparing aspirin 75 to 81 mg vs 150 to 162 mg for prevention of preterm preeclampsia: systematic review and meta-analysis","volume":"5","author":"Ghesquiere","year":"2023","journal-title":"Am J Obstet Gynecol MFM"},{"key":"R9-20260930","doi-asserted-by":"crossref","first-page":"e2410","DOI":"10.1055\/s-0043-1771260","article-title":"Efficacy and safety of aspirin 162 mg for preeclampsia prophylaxis in high-risk patients","volume":"41","author":"Ayyash","year":"2024","journal-title":"Am J Perinatol"},{"key":"R10-20260930","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMoa1704559","article-title":"Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia","volume":"377","author":"Rolnik","year":"2017","journal-title":"N Engl J Med"},{"key":"R11-20260930","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ajog.2016.09.076","article-title":"The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis","volume":"216","author":"Roberge","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"R12-20260930","doi-asserted-by":"crossref","first-page":"315.e1","DOI":"10.1016\/j.ajog.2024.06.038","article-title":"Aspirin 162 mg vs 81 mg for preeclampsia prophylaxis in high-risk obese individuals: a comparative effectiveness open-label randomized trial (ASPREO)","volume":"232","author":"Amro","year":"2025","journal-title":"Am J Obstet Gynecol"},{"key":"R13-20260930","doi-asserted-by":"crossref","first-page":"e2457828","DOI":"10.1001\/jamanetworkopen.2024.57828","article-title":"Prophylactic aspirin dose and preeclampsia","volume":"8","author":"Kupka","year":"2025","journal-title":"JAMA Netw Open"},{"key":"R14-20260930","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3109\/08037059209077502","article-title":"Prospective Randomized Open Blinded End-Point (PROBE) study: a novel design for intervention trials: Prospective Randomized Open Blinded End-Point","volume":"1","author":"Hansson","year":"1992","journal-title":"Blood Press"},{"key":"R15-20260930","first-page":"e1","article-title":"Gestational hypertension and preeclampsia. ACOG Practice Bulletin No. 202. American College of Obstetricians and Gynecologists","volume":"133","year":"2019","journal-title":"Obstet Gynecol"},{"key":"R16-20260930","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.preghy.2016.08.232","article-title":"Aspirin adherence during high-risk pregnancies, a questionnaire study","volume":"6","author":"Abheiden","year":"2016","journal-title":"Pregnancy Hypertens"},{"key":"R17-20260930","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/00002030-200203080-00012","article-title":"Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study","volume":"16","author":"Knobel","year":"2002","journal-title":"AIDS"},{"key":"R18-20260930","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ajog.2017.11.561","article-title":"Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis","volume":"218","author":"Roberge","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"R19-20260930","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ajog.2018.03.018","article-title":"Optimal aspirin dosing for preeclampsia prevention","volume":"219","author":"Seidler","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"R20-20260930","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(07)60712-0","article-title":"Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data","volume":"369","author":"Askie","year":"2007","journal-title":"Lancet"},{"key":"R21-20260930","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jogc.2022.03.002","article-title":"Guideline No. 426: hypertensive disorders of pregnancy: diagnosis, prediction, prevention, and management","volume":"44","author":"Magee","year":"2022","journal-title":"J Obstet Gynaecol Can"},{"key":"R22-20260930","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/jch.14821","article-title":"The optimal dosage of aspirin for preventing preeclampsia in high-risk pregnant women: a network meta-analysis of 23 randomized controlled trials","volume":"26","author":"Hu","year":"2024","journal-title":"J Clin Hypertens"},{"key":"R23-20260930","doi-asserted-by":"crossref","first-page":"685.e1","DOI":"10.1016\/j.ajog.2017.08.110","article-title":"Aspirin for evidence-based preeclampsia prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia","volume":"217","author":"Wright","year":"2017","journal-title":"Am J Obstet Gynecol"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000006100","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:00:47Z","timestamp":1790780447000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000006100"}},"subtitle":["A Randomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000006100","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"2025-05-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}